136 related articles for article (PubMed ID: 23268610)
1. Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis.
Jin X; Ding C
Expert Opin Biol Ther; 2013 Feb; 13(2):315-22. PubMed ID: 23268610
[TBL] [Abstract][Full Text] [Related]
2. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.
Stohl W; Merrill JT; McKay JD; Lisse JR; Zhong ZJ; Freimuth WW; Genovese MC
J Rheumatol; 2013 May; 40(5):579-89. PubMed ID: 23547209
[TBL] [Abstract][Full Text] [Related]
4. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases.
Ding C
Expert Opin Biol Ther; 2008 Nov; 8(11):1805-14. PubMed ID: 18847314
[TBL] [Abstract][Full Text] [Related]
5. A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia.
Bishton M; Spencer A; Dickinson M; Ritchie D
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):575-8. PubMed ID: 23773449
[TBL] [Abstract][Full Text] [Related]
6. Belimumab: anti-BLyS monoclonal antibody; Benlysta; BmAb; LymphoStat-B.
Drugs R D; 2010; 10(1):55-65. PubMed ID: 20509716
[TBL] [Abstract][Full Text] [Related]
7. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
[TBL] [Abstract][Full Text] [Related]
8. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.
Halpern WG; Lappin P; Zanardi T; Cai W; Corcoran M; Zhong J; Baker KP
Toxicol Sci; 2006 Jun; 91(2):586-99. PubMed ID: 16517838
[TBL] [Abstract][Full Text] [Related]
9. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
[TBL] [Abstract][Full Text] [Related]
10. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
11. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline.
Ding C; Jones G
Curr Opin Investig Drugs; 2006 May; 7(5):464-72. PubMed ID: 16729724
[TBL] [Abstract][Full Text] [Related]
12. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
Mosak J; Furie R
Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
[TBL] [Abstract][Full Text] [Related]
13. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.
Wiglesworth AK; Ennis KM; Kockler DR
Ann Pharmacother; 2010 Dec; 44(12):1955-61. PubMed ID: 21081710
[TBL] [Abstract][Full Text] [Related]
14. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.
Yellin M; Paliienko I; Balanescu A; Ter-Vartanian S; Tseluyko V; Xu LA; Tao X; Cardarelli PM; Leblanc H; Nichol G; Ancuta C; Chirieac R; Luo A
Arthritis Rheum; 2012 Jun; 64(6):1730-9. PubMed ID: 22147649
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
Jordan NP; D'Cruz DP
Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
[TBL] [Abstract][Full Text] [Related]
16. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
La DT; Collins CE; Yang HT; Migone TS; Stohl W
Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study.
Quartuccio L; Salvin S; Corazza L; Gandolfo S; Fabris M; De Vita S
Clin Exp Rheumatol; 2016; 34(2):311-4. PubMed ID: 26886154
[TBL] [Abstract][Full Text] [Related]
18. Post-marketing experiences with belimumab in the treatment of SLE patients.
Askanase AD; Yazdany J; Molta CT
Rheum Dis Clin North Am; 2014 Aug; 40(3):507-17, viii. PubMed ID: 25034159
[TBL] [Abstract][Full Text] [Related]
19. [Research progress on B cell surface molecules targeted therapy in rheumatoid arthritis].
Di W; Chang Y; Wu YJ; Wei W
Sheng Li Ke Xue Jin Zhan; 2011 Jun; 42(3):175-80. PubMed ID: 21932514
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]